公开(公告)号：US09932375B2

公开(公告)日：2018-04-03

申请号：US15285830

申请日：2016-10-05

Applicant: VAR2 PHARMACEUTICALS APS

Inventor： Ali Salanti ,  Thor Grundtvig Theander ,  Mads Daugaard ,  Morten Nielsen ,  Madeleine Dahlback ,  Thomas Mandel Clausen

IPC: A61K39/00 ,  A61K39/38 ,  C07K14/445 ,  A61K38/16 ,  A61K38/45 ,  A61K49/00 ,  A61K51/08 ,  G01N33/574 ,  C07K14/21 ,  C07K14/34 ,  A61K38/00

CPC classification number: C07K14/445 ,  A61K38/00 ,  A61K38/16 ,  A61K38/45 ,  A61K49/00 ,  A61K49/0056 ,  A61K51/088 ,  C07K14/21 ,  C07K14/34 ,  C07K2319/33 ,  C12Y204/02036 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/47 ,  G01N2333/70585

Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).

公开(公告)号：US20170370917A1

公开(公告)日：2017-12-28

申请号：US15694592

申请日：2017-09-01

Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Inventor： Donal Mackernan ,  Shourjya Sanyal

IPC: G01N33/542 ,  C07K14/47 ,  G01N33/58 ,  G01N21/64 ,  C12N9/12 ,  C12N9/10 ,  A61K38/00

CPC classification number: G01N33/542 ,  A61K38/00 ,  C07K14/47 ,  C07K2319/55 ,  C07K2319/61 ,  C12N9/1077 ,  C12N9/12 ,  C12N15/62 ,  C12Y204/02036 ,  C12Y207/11011 ,  G01N21/6428 ,  G01N33/582 ,  G01N2021/6439

Abstract: The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod-like molecule L opposite to the joint molecule C; (c) a binding molecule A′ bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to the target molecule to be detected, and binding molecule A′ is arranged to bind to: i) the same target molecule as target binding molecule A; or ii) a complex of the target binding molecule A and the target; and wherein the hinge is biased into an open position, such that target binding molecule A and binding molecule A′ are biased apart by the hinge.

公开(公告)号：US09758552B2

公开(公告)日：2017-09-12

申请号：US14386470

申请日：2013-03-19

Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT

Inventor： Daniel Gillet ,  Benoit Villiers ,  Sylvain Pichard ,  Bernard Maillere ,  Alain Sanson

IPC: C07K14/00 ,  C07K14/195 ,  C07K14/34 ,  A61K38/16 ,  C12N9/10 ,  G01N33/74 ,  A61K38/00 ,  A61K48/00

CPC classification number: C07K14/34 ,  A61K38/00 ,  A61K38/164 ,  A61K48/00 ,  C12N9/1077 ,  C12Y204/02036 ,  G01N33/74

Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.

公开(公告)号：US09676826B2

公开(公告)日：2017-06-13

申请号：US15098210

申请日：2016-04-13

Applicant: TheVax Genetics Vaccine Co., Ltd.

Inventor： Wei-I Chou ,  Chia-Mao Wu ,  Jiun-Ming Wu ,  Hsiu-Kang Chang

IPC: C07K14/21 ,  C07K19/00 ,  A61K39/02 ,  A61K39/385 ,  A61K39/21 ,  C07K14/005 ,  A61K47/48 ,  C07K14/705 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  C07K14/81 ,  C12N9/10 ,  C12N9/14 ,  A61K39/29 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/135 ,  A61K39/17 ,  A61K39/21 ,  A61K39/29 ,  A61K39/292 ,  A61K39/385 ,  A61K2039/57 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K14/21 ,  C07K14/70596 ,  C07K14/81 ,  C07K2319/02 ,  C07K2319/04 ,  C07K2319/095 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/1077 ,  C12N9/14 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2750/10022 ,  C12N2750/10034 ,  C12N2760/18134 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2770/24334 ,  C12N2770/32134 ,  C12Y204/02036 ,  C12Y306/05002 ,  Y02A50/386

Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

公开(公告)号：US20170151307A1

公开(公告)日：2017-06-01

申请号：US15309177

申请日：2015-05-07

Applicant: Applied Molecular Transport LLC

Inventor： Randall J Mrsny ,  Tahir Mahmood

IPC: A61K38/16 ,  A61K38/27 ,  A61K38/20

CPC classification number: A61K38/45 ,  A61K38/164 ,  A61K38/166 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2066 ,  A61K38/26 ,  A61K38/27 ,  A61K38/482 ,  A61K38/49 ,  A61K38/50 ,  A61K38/51 ,  C07K14/5428 ,  C07K16/241 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/90 ,  C12Y204/02036 ,  C12Y304/21068 ,  C12Y304/21073 ,  C12Y305/04004 ,  C12Y402/02001

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

公开(公告)号：US20170137475A1

公开(公告)日：2017-05-18

申请号：US15210245

申请日：2016-07-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Normand BLAIS ,  Philippe Marc Helene DEHOTTAY ,  Marianne DEWERCHIN ,  Philippe GOFFIN ,  Denis MARTIN

IPC: C07K14/34 ,  C12N9/10

CPC classification number: C07K14/34 ,  C07K1/00 ,  C07K2319/034 ,  C12N9/1077 ,  C12Y204/02036

Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.

公开(公告)号：US09518119B2

公开(公告)日：2016-12-13

申请号：US14632178

申请日：2015-02-26

Applicant: Stemline Therapeutics, Inc.

Inventor： Ivan Bergstein

IPC: C12P21/02 ,  C07K16/28 ,  C12N9/10 ,  C12N15/86 ,  C12P21/06 ,  C12N15/64 ,  C12N5/16 ,  C07K14/705 ,  A61K39/00 ,  C07K16/18

CPC classification number: C07K16/2866 ,  A61K39/00 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/55 ,  C12N5/163 ,  C12N9/1048 ,  C12N9/1077 ,  C12N15/86 ,  C12Y204/02036

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3Rα-expressing cell population, the methods comprising contacting a population of IL3Rα-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3Rα. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3Rα chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3Rα-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3Rα.

公开(公告)号：US09422345B2

公开(公告)日：2016-08-23

申请号：US13500244

申请日：2010-10-07

Applicant: Normand Blais ,  Philippe Marc Helene Dehottay ,  Marianne Dewerchin ,  Philippe Goffin ,  Denis Martin

Inventor： Normand Blais ,  Philippe Marc Helene Dehottay ,  Marianne Dewerchin ,  Philippe Goffin ,  Denis Martin

IPC: C07H21/04 ,  C07K14/34

CPC classification number: C07K14/34 ,  C07K1/00 ,  C07K2319/034 ,  C12N9/1077 ,  C12Y204/02036

Abstract: Polynucleotides are provided herein.

Abstract translation: 本文提供多核苷酸。

公开(公告)号：US09409994B2

公开(公告)日：2016-08-09

申请号：US14403896

申请日：2013-05-31

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Mitchell Ho ,  Yen T. Phung ,  Wei Gao ,  Yifan Zhang

IPC: C07K16/30 ,  A61K39/395 ,  G01N33/68 ,  A61K38/45 ,  A61K47/48 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/3069 ,  A61K38/45 ,  A61K47/48569 ,  A61K47/48638 ,  A61K47/6851 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y204/02036 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2458/00

Abstract: Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.

Abstract translation: 本文描述了一组结合GPC3的高亲和力单克隆抗体的鉴定。 所公开的抗体识别癌细胞表面上的天然GPC3，以及可溶性GPC3。 进一步表征最高亲和力抗体（YP7），显示出高度敏感性，因为它能够检测到具有低GPC3表达的癌细胞。 YP7在体内也表现出显着的HCC肿瘤生长抑制作用。 与PE38融合的包含本文公开的抗体的免疫毒素对GPC3表达细胞表现出非常高的结合亲和力，并显着抑制表达GPC3的癌细胞生长。 因此，本文公开的高亲和力单克隆抗体可用于诊断和治疗表达GPC3的癌症。

公开(公告)号：US20160108377A1

公开(公告)日：2016-04-21

申请号：US14984006

申请日：2015-12-30

Applicant: Intrexon Corporation

Inventor： Timothy David Jones ,  Francis Joseph Carr

IPC: C12N9/10

CPC classification number: C12N9/1077 ,  A61K38/00 ,  A61K39/00 ,  A61K39/02 ,  C07K14/21 ,  C07K16/2803 ,  C07K2317/622 ,  C12Y204/02036

Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.